Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Thymidylate synthase (TS) overexpression is a key determinant of 5-fluorouracil (5-FU) resistance in human cancer cells. TS is also acutely up-regulated with 5-FU treatment, and, thus, novel strategies targeting TS down-regulation seem to be promising in terms of modulating 5-FU resistance. Here, we report that histone deacetylase inhibitors can reverse 5-FU resistance by down-regulating TS. By using cDNA microarrays and validation experiments, we found that trichostatin A reduced the expression of both TS mRNA and TS protein. Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis. On the other hand, TS protein expression was significantly reduced by lower doses of trichostatin A (50 nmol/L). Mechanistically, TS protein was found to interact with heat shock protein (Hsp) complex, and trichostatin A treatment induced chaperonic Hsp90 acetylation and subsequently enhanced Hsp70 binding to TS, which led to the proteasomal degradation of TS protein. Of note, combined treatment with low-dose trichostatin A and 5-FU enhanced 5-FU–mediated cytotoxicity in 5-FU–resistant cancer cells in accordance with TS protein down-regulation. We conclude that a combinatorial approach using histone deacetylase inhibitors may be useful at overcoming 5-FU resistance. [Mol Cancer Ther 2006;5(12):3085–95]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 2×
“HDACIs are classified into hydroxamic acid, short-chain fatty acid, benzamide, cyclic tetrapeptide, and hybrid compounds according to their chemical structure (25, 45, 46).”
BackgroundModulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Yu, X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.504 · Cited by 360 · cited 2×
“It was recently reported that HDACIs acetylate Hsp90, and that this results in the degradation of client oncoproteins via the proteasomal pathway (37).”
Background
Cited by
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Histone Deacetylase Inhibitors: From Bench to Clinic
Paris, M., Porcelloni, M., Binaschi, M., & Fattori, D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7011408 · Cited by 367
HDAC inhibitors: Clinical update and mechanism-based potential
Glaser, K. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.04.007 · Cited by 348
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 291
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
O'Donnell, P. H., & Dolan, M. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0344 · Cited by 261
Metadata
- Authors
- Lee, J.-H., Park, J.-H., Jung, Y., Kim, J.-H., Jong, H.-S., Kim, T.-Y., & Bang, Y.-J.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 3085-3095
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2114166108
- Cited by
- 101
- References
- 2
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0419
- The paper
- Lee, J.-H., Park, J.-H., Jung, Y., Kim, J.-H., Jong, H.-S., Kim, T.-Y., & Bang, Y.-J. (2006). Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.